Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Host factors in HIV RNA metabolism as potential therapeutic targets

EF 2009-10

Résumé
The Human Immunodeficiency Virus (HIV) represents a serious human health concern where more drugs are needed to combat cases of drug resistance in AIDS patients. Most current HIV drugs target proteins the virus produces, however there are a large subset of proteins present in the infected cell which HIV takes advantage of and are actually essential for its replication cycle. These represent an untapped source of potential drug targets. HIV is a retrovirus which integrates into the host genomic DNA and becomes a provirus. It then must transcribe this proviral DNA into RNA and export it from the nucleus of the host cell into the cytoplasm. HIV produces a large number of proteins from its small genome, requiring the production of different sizes and types of viral RNA through RNA splicing. This differential splicing requires different export mechanisms as normally only fully spliced RNA is exported. Regulation of viral RNA metabolism involves interplay between sequences on the RNA as well as a large number of host proteins that control splicing and export. These are the host factors which, if regulated by drugs, have the potential to inhibit HIV replication. A promising avenue of research will explore the potential of using existing FDA and Health Canada approved drugs to target these host proteins. A preliminary drug screen has already shown that clinically used drugs digoxin and chlorohexidine strongly inhibit HIV-1 expression by interacting with one set of host proteins involved in HIV RNA metabolism, Clk1-4. A more extensive screen of a similar class of approved drugs has a possibility to reveal even more HIV-1 inhibiting drugs. Determining the mechanism of action of these potential drugs will also be explored.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
200999
Name
Bragg Jason
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Host factors in HIV RNA metabolism as potential therapeutic targets
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Drug Targets; Hiv; Rna Metabolism
Abstract
The Human Immunodeficiency Virus (HIV) represents a serious human health concern where more drugs are needed to combat cases of drug resistance in AIDS patients. Most current HIV drugs target proteins the virus produces, however there are a large subset of proteins present in the infected cell which HIV takes advantage of and are actually essential for its replication cycle. These represent an untapped source of potential drug targets. HIV is a retrovirus which integrates into the host genomic DNA and becomes a provirus. It then must transcribe this proviral DNA into RNA and export it from the nucleus of the host cell into the cytoplasm. HIV produces a large number of proteins from its small genome, requiring the production of different sizes and types of viral RNA through RNA splicing. This differential splicing requires different export mechanisms as normally only fully spliced RNA is exported. Regulation of viral RNA metabolism involves interplay between sequences on the RNA as well as a large number of host proteins that control splicing and export. These are the host factors which, if regulated by drugs, have the potential to inhibit HIV replication. A promising avenue of research will explore the potential of using existing FDA and Health Canada approved drugs to target these host proteins. A preliminary drug screen has already shown that clinically used drugs digoxin and chlorohexidine strongly inhibit HIV-1 expression by interacting with one set of host proteins involved in HIV RNA metabolism, Clk1-4. A more extensive screen of a similar class of approved drugs has a possibility to reveal even more HIV-1 inhibiting drugs. Determining the mechanism of action of these potential drugs will also be explored.
Competitiondate
201002
Approvedterm2
1 yr 0 mth
Pinamesdelim
Bragg, Jason
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~